Julia Bonavitacola

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help to improve access to clinical trials on a national and local level, explains Eric Lander, MD, of Minnesota Oncology.

The recent approval of lenacapavir could change the way that clinicians approach both treating and preventing HIV in those at risk, as long as the treatment can get into their hands.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving vaccine research and expertise behind.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The announcement of the new members of the CDC Advisory Committee on Immunization Practice comes days after the HHS secretary removed all previous members of the panel.

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.

Those who developed primary open-angle glaucoma (POAG) had lower mental health scores compared with those who had not developed the condition.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

Artificial intelligence (AI) provides a major tool in the evolution of thoracic care, as clinicians work to catch lung cancer earlier to provide better prognosis.

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

With potential lung cancer nodules sometimes slipping through the cracks, educating stakeholders about artificial intelligence (AI) that can catch nodules early could be helpful in cancer treatment.

Pentacam and corneal topography were more sensitive to tear film abnormalities when measuring the curvature of the cornea in those with dry eye.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.

Mental health outpatient services decreased in adults aged 65 years and older who were eligible for Medicare.

Decisions made during the first few months of the Trump administration do not inspire confidence in Ali Khawar for further protections for parity in coverage of mental health.

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The HHS secretary has suggested that he will bar all government scientists from publishing in the top medical journals in the country.